Our results suggest that the development of future drugs aimed at diabetes-induced renal hypertrophy should incorporate the nucleolus, and in particular nucleolin, as a marker to test the efficacy of new lead compounds. This evidence concerns the gene NUCLEOLIN and diabetes mellitus.